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X-linked primary ciliary dyskinesia due to mutations
in the cytoplasmic axonemal dynein assembly
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Antoine Garin15, Isabelle Pin16, Gabriella Vera9, Paul Aurora17,18, Mahmoud R. Fassad3,19, Lucy Jenkins20,
Christopher Boustred20, Thomas Cullup20, Mellisa Dixon4, Alexandros Onoufriadis21, Andrew Bush4,22,
Eddie M.K. Chung23, Stylianos E. Antonarakis1,12,24, Michael R. Loebinger25, Robert Wilson25, Miguel Armengot26,
Estelle Escudier6, Claire Hogg4, UK10K Rare Groupw, Serge Amselem6,**, Zhaoxia Sun5,**, Lucia Bartoloni1,27,**,
Jean-Louis Blouin1,12,** & Hannah M. Mitchison3,**
By moving essential body ﬂuids and molecules, motile cilia and ﬂagella govern respiratory mucociliary
clearance, laterality determination and the transport of gametes and cerebrospinal ﬂuid. Primary ciliary
dyskinesia (PCD) is an autosomal recessive disorder frequently caused by non-assembly of dynein arm
motors into cilia and ﬂagella axonemes. Before their import into cilia and ﬂagella, multi-subunit
axonemal dynein arms are thought to be stabilized and pre-assembled in the cytoplasm through a DNAAF2–
DNAAF4–HSP90 complex akin to the HSP90 co-chaperone R2TP complex. Here, we demonstrate that large
genomic deletions as well as point mutations involving PIH1D3 are responsible for an X-linked form of PCD
causing disruption of early axonemal dynein assembly. We propose that PIH1D3, a protein that emerges as a
new player of the cytoplasmic pre-assembly pathway, is part of a complementary conserved R2TP-like
HSP90 co-chaperone complex, the loss of which affects assembly of a subset of inner arm dyneins.
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n mammals, motile cilia are abundant (200–300 per cell)
in multiciliated cells lining various specialized epithelia,
including the airways, the oviduct and ependyma. The motile
cilium is highly similar in structure to the motile ﬂagella of sperm,
being a long cellular projection sustained by a complex
cytoskeleton structure (axoneme) composed of 4200 proteins.
Motile cilia axonemes are composed of nine peripheral micro-
tubule doublets surrounding two central microtubules (9þ 2)
except for motile cilia of the embryonic node, which lack the
central apparatus (9þ 0). Several other structures attach along the
length of the microtubules at 96-nm intervals to coordinate
axonemal beating, including ATP-hydrolysing motor protein
complexes called the outer dynein ‘arms’ (ODAs) and inner
dynein arms (IDAs), as well as radial spokes and nexin–dynein
regulatory complexes1.
Structural or ciliogenesis defects that affect cilia motility cause
primary ciliary dyskinesia (PCD), a generally autosomal recessive
disorder affecting 1 per 10,000–15,000 live births2,3. Typical
features are chronic and progressive respiratory symptoms arising
from deﬁcient mucociliary clearance of the airways, manifesting
in diffuse congestive lung disease and bronchiectasis. Since sperm
ﬂagella are structurally similar to cilia, PCD has a high rate of
male infertility. Laterality defects arising from dysmotile nodal
cilia affect half of patients, causing situs inversus or often more
complex heterotaxies and congenital heart defects4. PCD is
clinically and genetically heterogeneous with mutations in 430
genes causing disease2. A common defect is loss of both ODAs
and IDAs from the ciliary axonemes, due to mutations in genes
encoding axonemal dynein assembly (‘DNAAF’) and attachment
factors including DNAAF1/LRRC50 (refs 5,6), DNAAF2/KTU7,
DNAAF3 (ref. 8), DNAAF4/DYX1C1 (ref. 9), DNAAF5/
HEATR2 (refs 10,11), SPAG1 (ref. 12), C21ORF59 (ref. 13),
LRRC6 (refs 14,15), ZMYND10 (refs 16,17) and CCDC103
(refs 18,19). The joint loss of the ODAs and IDAs is one of the
most variable ultrastructural defects underlying PCD since
affected individuals often have partial defects and truncated
dynein arms7,9,12,13,16,19.
The assembly of dynein arms into cilia is a highly
evolutionarily conserved mechanism within the cytoplasm.
Dynein components synthesized in the cell body are
pre-assembled into multi-subunit ‘arm’ structures, which are
transported by intraﬂagellar transport (IFT) into the axoneme for
microtubule attachment20,21. The stabilization, folding and
pre-assembly of the dynein arm motors is governed by a
cytoplasmic chaperone-mediated protein network20,22,23. ODA
assembly is thought to involve chaperone-mediated attachment of
intermediate chain (IC) dyneins DNAI1 and DNAI2 to heavy
chain (HC) dyneins (DNAH5, DNAH11). This IC–HC assembly
is facilitated by DNAAF1, DNAAF2 and DNAAF3, with
DNAAF3 probably acting at the ﬁnal stages of chaperone
dissociation8. DNAAF2 binds at least one IC (DNAI2), heat
shock protein (HSP) 70 (ref. 7), as well as DNAAF4 which itself
can bind both HSP70 and HSP90 (refs 9,24). DNAAF2–DNAAF4
were recently described as an R2TP-like co-chaperone complex,
similarly recruited to HSP90 for assembly and regulation of
multi-subunit complexes25,26. Other cytoplasmic axonemal
dynein assembly factors are also emerging to have likely
chaperone functions, for example C21ORF59 (ref. 27).
Here, by studying the molecular basis of PCD in unexplained
cases, we have identiﬁed a new player in this cytoplasmic
pre-assembly pathway, mutations in which cause X-linked disease
and a variable loss of cilia dynein arms in both human PCD and
the corresponding zebraﬁsh PCD model. From structural,
functional and clinical electron tomography data, we propose
this might act in a complementary module akin to the
DNAAF2–DNAAF4–HSP90 co-chaperone complex.
Results
PIH1D3 mutations cause PCD. A number of approaches
were used by three molecular genetics laboratories (London,
Geneva and Paris) to identify novel mutations causing PCD:
next-generation sequencing (NGS) of whole exomes of affected
individuals from 76 families, a targeted gene panel in affected
individuals from 133 families and whole-genome SNP-array
analyses in a male patient with intellectual disability and two male
siblings from a consanguineous union. The identiﬁcation of
putative mutations in the X-linked gene PIH1D3 in different
patients prompted us to screen this gene by Sanger sequencing in
a cohort of 32 independent male patients; this targeted screening
identiﬁed a high proportion of affected families, with four males
from three families carrying PIH1D3 mutations (9.5% (3/32) of
independent cases screened). Overall, these studies led to the
identiﬁcation of PIH1D3 molecular defects in affected males from
nine independent families, which were all family-unique (Fig. 1a;
Supplementary Figs 1 and 2): three nonsense mutations
(c.127G4T, p.Glu43* in PCD12 II:1; c.266G4A, p.Trp89* in
PCD392 II:1; c.511C4T, p.Gln171* in DCP1218), two frameshift
mutations (c.263_268delinsG, p.Ile88Argfs*12 in DCP894;
c.489_492del; p.Ile164Leufs*11 in GVA30 II:1), one missense
change (c.397G4T, p.Asp133Tyr in DCP68), as well as genomic
deletions containing the PIH1D3 gene (1.93-Mb, 3.27-Mb and
3.73-Mb deletions in DCP603/DCP1747, DCP1337 and DCP855,
respectively). The complement of genes contained within the
latter, larger deletions are listed in Supplementary Table 1. In the
NGS screening no other variants of interest were detected, and all
the nine identiﬁed PIH1D3 variants were unique, having never
been previously reported and being absent from all available
databases of normal human variation (ExAC, 1000G, EVS). The
nonsense, frameshift and deletion mutations are all predicted as
protein disrupting and Fig. 1b shows a high level of conservation
of Asp133 which is located within a key surface domain of
PIH1D3, as described further below.
The affected families are of European origin except for PCD392
from Sri Lanka and the affected brothers DCP603 and DCP1747
from the sole consanguineous family (DC393) who are from
Morocco (Supplementary Fig. 1; Supplementary Table 2).
Familial segregation analysis by Sanger sequencing showed
inheritance consistent with recessive X-linked disease in all cases,
an inheritance pattern never before shown for non-syndromic
PCD (Supplementary Fig. 1). Over-expressed mutated
GFP-tagged PIH1D3 showed results consistent with the expected
effect on the protein (Supplementary Fig. 3). Of the total 13
affected males, 6 had situs inversus totalis which is consistent
with the typical PCD randomized left–right body plan. All have
classic PCD features including neonatal respiratory distress,
recurrent respiratory infections, chronic cough, sinusitis,
recurrent pneumonia, otitis media and bronchiectasis
(Supplementary Table 2). PCD392 II:1 had developmental delay
considered unrelated to PCD and the affected individuals
DCP855 and DCP1337 carrying larger chromosomal deletions
of43Mb affecting multiple genes also had intellectual disability.
Sperm motility tested in ﬁve affected men carrying PIH1D3
mutations showed that all had static ﬂagella (asthenozoospermia)
(Supplementary Table 2).
PIH1D3 is a putative axonemal dynein assembly factor. As a
ﬁrst step in investigating the likely function of PIH1D3, we
looked at the domain organization of the protein. PIH1D3 is
predicted with high conﬁdence not to contain a ‘PIH’ domain
(‘protein interacting with heat shock protein 90’), but rather to
contain a highly conserved ‘CS’ fold occupying 40% of the protein
(Fig. 1a; Supplementary Fig. 4). PIH and CS are structurally
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distinct domains, although found in functionally similar proteins.
The CS is a bipartite protein–protein interaction domain
(Interpro #007052) so called because it is shared by CHORD
(cysteine- and histidine-rich domain)-containing proteins and the
HSP90 co-chaperone SGT1 (suppressor of the G2 allele of
Skp1)7,9,28. CS domains are also found in other HSP90
co-chaperones and protein folding proteins29. In contrast, the
N-terminal domain of PIH1D3 lacks any identiﬁable domain and
is predicted with high conﬁdence to be disordered, that is,
without ﬁxed structure, although it contains several strongly
conserved regions that might have functional importance perhaps
through binding to partner proteins (Supplementary Fig. 4).
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To further investigate the possible role of PIH1D3 in cilia
motility, we performed cross-species BLAST analyses, showing
that PIH1D3 is a highly conserved protein present only in species
that have motile cilia/ﬂagella containing dynein arms and those
that require IFT for ciliary assembly (Supplementary Fig. 5).
This supports a role for PIH1D3 in IFT-related dynein arm
assembly. Phylogenetic evolutionary analysis showed that while
humans have a single X-linked copy of PIH1D3, mice have
two homologous copies located on chromosomes 1 and X
(Supplementary Fig. 6). The intronless Chr. 1 mouse gene is most
likely an expressed pseudogene recently diverged from and
younger than the presumed ancient, intron-containing Chr. X
gene. The proteins expressed from the murine Chr. 1 and Chr. X
copy are 91% identical, differing mainly in the unstructured N
terminus (Supplementary Fig. 4b). Knockout mice lacking the
exclusively testis-expressed intronless mouse chromosome 1
pseudogene (that has been termed Pih1d3, 4930521A18Rik) have
immotile sperm ﬂagella with dynein arm defects and male
sterility, but notably do not manifest situs inversus, respiratory
cilia dysfunction, hydrocephalus or any ciliary phenotypes typical
of PCD30. The testis-speciﬁc Pih1d3 is not detectable in the
mouse node at day 8, when embryonic symmetry is ﬁrst broken,
and this correlates with the knockouts never showing situs
inversus30. The knockouts still express the mouse X-linked gene
(called Pih1h3b, E230019M04Rik), which is expressed more
widely than testis, also in the lung, brain and oviduct, but is
evidently not able to rescue the sperm ﬂagella defect arising from
loss of the Chr. 1 copy30. This evolutionary evidence shows a role
for PIH1D3 in dynein arm assembly, a role that appears to have
recently diverged in mice being governed by different proteins
expressed in mouse sperm ﬂagella and cilia, with the cilia-
expressed X-linked copy unable to compensate for the Chr. 1
copy in sperm. This contrasts with our data in humans showing
that X-linked mutations in the sole human PIH1D3 gene cause
both cilia and sperm defects.
To further investigate the likely function of PIH1D3, we
determined where the protein is expressed in cells using a
PIH1D3-speciﬁc antibody (demonstrated in Supplementary
Fig. 3) and high-resolution immunoﬂuorescence confocal micro-
scopy imaging in ciliated respiratory epithelial cells from healthy
controls and PIH1D3 mutation carriers. A speciﬁc localization
within the cytoplasm was detected with strong staining
of PIH1D3 observed in proximity to the nucleus, but no
co-localization with ciliary basal body or axonemal markers
(g-tubulin and acetylated-a tubulin, respectively). The cyto-
plasmic localization of PIH1D3 further supports its putative role
in PCD as a cytoplasmic axonemal dynein assembly factor5–10,15.
Notably, in cells from PIH1D3-mutated individuals GVA30 II:1
(p.Ile164Leufs*11) and PCD12 II:1 (p.Glu43*) a marked
reduction of PIH1D3 protein staining was seen, with very faint
staining in PCD12 II:1 and undetectable levels in GVA30 II:1
(Fig. 1c).
PIH1D3mutations confer variable dynein arm defects. We next
investigated the effect of PIH1D3 mutations at the ultrastructural
level by transmission electron microscopy (TEM) of PIH1D3-
mutated respiratory cilia, performed within two clinical centres
employing multiple replicates analysing4300 cilia cross-sections
per replicate. This revealed in all available cases but to variable
degree, a loss of both the ODAs and IDAs (Fig. 2; Supplementary
Table 2). The spectrum of dynein arm loss arising from PIH1D3
mutation comprised cilia from GVA30 II:1, DCP855, DCP1337,
DCP603, DCP1747, DCP894, DCP1218 and DCP68 displaying
an almost complete loss of both ODA and IDA in available
samples with hardly any normal cross-sections apparent, whilst
PCD392 II:1 (p.Trp89*) displayed comparatively less IDA loss
still with extensive loss of ODAs (Fig. 2b). However, PCD12 II:1
(p.Glu43*) appeared to be an unusual outlier, displaying much
less ODA loss and primarily an IDA loss phenotype (Fig. 2b).
We proceeded to investigate the effect of PIH1D3 mutations on
assembly of the ODAs and IDAs at the molecular level by
immunoﬂuorescence staining of PIH1D3-mutated respiratory
cilia using antibodies directed against two established markers of
human dynein arms, the dynein HC ODA marker DNAH5 and
dynein light IC IDA marker DNALI1. DNAH5 staining was
reduced in PIH1D3-mutated individuals, being undetectable in
the axonemes of GVA30 II:1 (p.Ile164Leufs*11), corroborating
with the TEM evidence of disrupted ODA assembly (Fig. 3a).
In PCD12 II:1 (p.Glu43*) staining was greatly reduced as well, but
some retention of DNAH5-stained ODAs was apparent, which is
consistent with the TEM data shown in Fig. 2. Another ODA
marker, the intermediate dynein chain DNAI2, and DNALI1
were analysed and found to display similar reduced levels in the
cilia axonemes of GVA30 II:1 (p.Ile164Leufs*11) and PCD12 II:1
(p.Glu43*), again with more apparent retention of both in PCD12
II:1 (Fig. 3b). This supports the TEM ﬁndings that PCD12 II:1
retains more of the ODAs than GVA30 II:1, and also some IDAs.
The variable retention of ODAs and IDAs in PIH1D3-mutated
cilia mirrors the variable effects of different mutations in some
other known dynein assembly factor PCD genes7,9,12,13,16. In the
case of PCD12 II:1 (p.Glu43*), in spite of the PIH1D3 nonsense
mutation there appears to be less severe loss of ODAs than that of
the other patients, suggesting a less severe mutation. The
involvement of modifying genetic factors cannot be excluded in
this individual; alternatively, the resulting PIH1D3 transcripts
may escape, at least in part, degradation via the nonsense-
mediated mRNA decay (NMD) pathway and the protein may
retain some degree of normal function. In keeping with
this hypothesis, the Human Splicing Finder V3.0 tool
Figure 1 | Location of X-linked PIH1D3 mutations and reduced cytoplasm-localized PIH1D3 protein in airway epithelia of affected individuals.
(a) PIH1D3 (CXorf41) on the X chromosome has two alternate transcripts NM_001169154.1 and NM_173494.1 differing by the presence of an extra
untranslated exon (exon 2) in NM_001169154.1. The open reading frame is contained in exon 3–8 (blue boxes). The PIH1D3 mutations identiﬁed are
shown within the 214 amino acid protein, in relation to its sole identiﬁable functional domain, a CS (named after CHORD-containing proteins and SGT1)
domain-spanning residue 128–214 (ScanProsite). Mutations are labelled according to the ﬁrst affected male screened per family. (b) Cross-species
conservation of the mutated amino acid Asp133 (D133) is shown beneath the protein, in red (right), and PHYRE-based63 three-dimensional modelling of
the whole of human PIH1D3 shows a surface representation of the highly conserved C-terminal CS domain, within which the Asp133 is predicted to be a
surface residue (in magenta) (left). Also highlighted are the beta sheet of the CS domain (yellow), the loops within the CS domain that join the beta strands
(white) and the long loop within the CS domain on which Asp133 is located (orange). In dark blue, the disordered N terminus lacks any known structural
domains. The effect of the mutated Tyr133 residue is shown (middle). (c) Immunoﬂuorescence confocal microscopy analysis of PIH1D3 (red) in dissociated
airway (nasal) epithelial cells from controls showed speciﬁc localization within the cell body in proximity to the nucleus (DAPI, blue) and no co-localization
with ciliary basal body or axonemal markers (g-tubulin and acetylated-a tubulin, respectively, green) (upper panel). In cells from PIH1D3-mutated
individuals GVA30 II:1 and PCD12 II:1 (middle and lower panels) there is marked reduction of PIH1D3 protein staining with undetectable levels in GVA30 II:1.
Differential interference contrast (DIC) microscopy shows the outline of the cells. Scale bars, 10mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14279
4 NATURE COMMUNICATIONS | 8:14279 | DOI: 10.1038/ncomms14279 | www.nature.com/naturecommunications
(http://www.umd.be/HSF3/index.html) predicts that the
c.127G4T mutation identiﬁed in PCD12 II:1 causes the loss of
a potential exonic splice enhancer (ESE) at the 30 end of exon 3
(Supplementary Fig. 7). This mutation is expected to alter
splicing, especially since the MaxEntScan application31 predicts
the strength of the physiological intron 3 donor splice site to be
very low (that is, score of 1.07, as compared with 7.97 to 11 for
the other PIH1D3 donor splice sites). On the basis of this
hypothesis, we performed RT-PCR on total RNA from a limited
amount of nasal biopsy material obtained from PCD12 II:1,
which conﬁrmed the absence of exon 3 from PIH1D3 transcripts
compared with those ampliﬁed from nasal biopsy of a healthy
control (Supplementary Fig. 8). This indicates that the PIH1D3
c.127G4T mutation causes an exon skipping event in PCD12
II:1 that removes exon 3 containing the normal ATG initiation
codon as well as the p.Glu43* nonsense mutation. This could
allow the use of an in-frame alternative ATG initiation codon,
downstream of the usual start codon located at the beginning of
exon 3. The corresponding transcripts would therefore escape
NMD and a shorter in-frame PIH1D3 protein could be expressed.
Such an alternative ATG indeed exists in exon 4 (codon 61) and it
contains a good Kozak consensus sequence as predicted by
ATGpr32 (score of 0.15 versus 0.16 for the usual ATG initiation
codon).
We investigated PIH1D3-mutated cilia motility using
high-speed video microscopy imaging. All affected individuals
ODA IDA
Radial 
spoke
Central
apparatus
a
b
DCP1337 p.3.27-Mb delDCP1218 p.Gln171*
100 nm
DCP894 
p.Ile88Argfs*12
PCD12 II:1 p.Glu43* GVA30 II:1 
p.Ile164Leufs*11
DCP68  p.Asp133Tyr DCP1747 1.93-Mb delDCP603 1.93-Mb del
PCD392 II:1 p.Trp89*
Control
Figure 2 | PIH1D3 mutations result in non-assembly and loss of IDAs and ODAs in respiratory cilia axonemes. (a) TEM showing the cross-section
arrangement of cilia from a healthy control (right) and an image (left) of the main structures of the 9þ 2 motile axoneme including the outer (ODA) and
inner (IDA) dynein arms (red arrowheads). (b) TEM of PIH1D3-mutant cilia from nasal respiratory epithelial cells of affected individuals display a reduction
and loss of both the ODAs and IDAs. All cases show a combined loss of ODAs and IDAs but this defect can be variable and in particular mutations
p.Glu43* (p.E43*, in PCD12 II:1) and p.Trp89* (p.W89*, in PCD392 II:1) are associated with some visible retention of the arms, in particular the outer
(PCD12) or inner (PCD392) dynein arms (red arrowheads). In comparison, all other mutations result in the majority of cross-sections showing complete
loss of both ODAs and IDAs. These images represent TEM data surveys from a minimum of 300 cross-sections per patient sample.
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Figure 3 | PIH1D3 mutations cause defective dynein arm assembly in respiratory cilia. (a) Respiratory epithelial cells from control and PCD-affected
individuals GVA30 II:1 and PCD12 II:1 carrying PIH1D3 mutations were double-labelled with antibodies directed against acetylated a-tubulin and g-tubulin
(green) to mark the ciliary axonemes and basal bodies, and DNAH5 as a marker of the ODA (red). Both a-tubulin and DNAH5 colocalize (yellow) along the
full length of the cilia axonemes in cells from the unaffected control (upper panel). In contrast, in cells from affected individuals GVA30 II:1
(p.Ile164Leufs*11) and PCD12 II:1 (p.Glu43*) (lower panels), DNAH5 is highly reduced in the ciliary axonemes compared with a-tubulin, being undetectable
in GVA30 II:1 and markedly reduced in PCD12 II:1. (b) Respiratory epithelial cells from control and PCD-affected individuals GVA30 II:1 and PCD12 II:1
carrying PIH1D3 mutations were also double-labelled with antibodies directed against another ODA marker DNAI2 (green) and the IDA marker DNALI1
(red). Both proteins colocalize (yellow) along the full length of the cilia axonemes in cells from the unaffected control (upper panel). In contrast, in the
PIH1D3 mutants, both DNAI2 and DNALI1 are reduced in the ciliary axonemes, being undetectable in GVA30 II:1 and markedly reduced in PCD12 II:1. DIC
shows the cell outline. Scale bars, 10mm.
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had immotile cilia consistent with dynein arm loss: as a
representative example of these patients, only entirely static cilia
could be seen in PCD392 II:1 (Supplementary Video 1), while in
controls a healthy coordinated beating pattern was observed
(Supplementary Videos 2 and 3). However in PCD12 II:1
(p.Glu43*) the cilia retained some movement, displaying within
the same sample a mixed beating pattern consisting of patches of
static cilia alongside patches of cilia beating with normal
frequency but a jittery dysmotile and disorganized pattern
(Supplementary Videos 4 and 5). Since ODAs govern cilia beat
frequency and propagate asymmetric waveforms, whilst IDAs
regulate cilia waveform and propagation33,34, we speculate that
the static cilia patches in PCD12 II:1 (p.Glu43*) correspond to
those more lacking in ODAs, whilst the cilia with retained but
disorganized beating could be those more lacking in IDAs.
PIH1D3 has a conserved ciliary role in other vertebrates.
We further investigated PIH1D3 function using zebraﬁsh
pih1d3hi1392Tg/hi1392Tg mutants generated by transgenic insertion.
Previous work identiﬁed a link in these mutants between loss of
PIH1D3 and cystogenesis within the glomerular-tubular region of
pronephric kidneys, but did not directly test for ciliary defects35.
We found that zebraﬁsh possess a single orthologous gene pih1d3
46% identical to human PIH1D3 (Supplementary Fig. 4b).
RT-PCR conﬁrmed that pih1d3 mRNA is maternally deposited
in zebraﬁsh, and is further expressed during the ﬁrst 2 days when
several ciliated organs become present (Supplementary Fig. 9).
hi1392Tg mutants consistently developed cysts in pronephric
glomeruli and tubuli (Fig. 4a,g). This phenotype was previously
linked to a lack of pronephric ﬂuid ﬂow caused by defective
pronephric cilia motility36, and is exhibited in hi1392Tg mutants
with visible pronephric dilation and dispersal of the normally
closely packed pronephric cilia (Supplementary Fig. 10)
We found that cilia are virtually immotile in hi1392Tg mutants,
both in pronephric tubuli and olfactory bulbs (Fig. 4b–d;
Supplementary Videos 6–9). TEM also revealed absent ODAs
and IDAs in mutant cilia, thus phenocopying human PIH1D3-
mutated patients (Fig. 4e,f). The hi1392Tg mutants additionally
displayed consistent ventral tail curvature that is typical for
PCD zebraﬁsh models, and two other phenotypes considered to
result from cilia dysmotility: abnormal cardiac looping presumed
to arise from defective Kupffer’s vesicle cilia motility37
and abnormal otolith formation caused by otic vesicle cilia
dysmotility38 (Fig. 4g). RT-PCR showed a complete lack of
expression of the hi1392Tg allele (Fig. 4h), and injecting zebraﬁsh
pih1d3 mRNA completely or largely rescues the phenotypes of
ventral body axis curvature, pronephric cysts and abnormal
cardiac looping (Supplementary Fig. 11).
To test whether PIH1D3 is functionally conserved from
zebraﬁsh to human, we injected human PIH1D3 mRNA into
embryos from crosses of heterozygous carriers of the hi1392Tg
allele. Overexpression of the human protein in zebraﬁsh appears
to be detrimental. By titrating the dosage down to 10 pg, the
ventral curvature phenotype is partially rescued in some of the
mutant embryos (Fig. 4i–k).
PIH1D3 acts early in dynein assembly with DNAI2 interaction.
We sought to further explore PIH1D3 ciliary function using the
human antibody that detects a speciﬁc protein product around
the Golgi region of the cytoplasm, near the nucleus (Fig. 1c).
High-resolution immunoﬂuorescence analysis revealed that
PIH1D3 localizes to the trans-Golgi network in ciliated epithelia
cells, with a high degree of speciﬁc co-localization between
PIH1D3 and the late Golgi marker TGN-46 but much less
colocalisation with the cis-Golgi marker GM-130 (Fig. 5a).
Co-localization with TGN-46 was also conﬁrmed after over-
expression of PIH1D3 in HEK293 cells (Supplementary Fig. 12).
PCD12 II:1 (p.Glu43*)-ciliated airway epithelial cells did not
show TGN disruption or loss of TGN-46 co-localization because
of their depleted PIH1D3 protein (Fig. 5a). Thus, any retained
protein expressed from this allele localizes normally. Expression
of PIH1D3 compared with two other PCD genes (DNAH5,
DNAI2) during ciliogenesis in cultured-ciliated human airway
epithelial cells showed a similar proﬁle, increasing before emer-
gence of the motile cilia around day 10, with peak expression
around day 24 falling to a lower plateau from day 24. Co-
expression of PIH1D3 with other PCD genes supports our pro-
posal that it has a shared function (Fig. 5b).
To further investigate the role of PIH1D3 in dynein assembly,
we examined its interactions with DNAI2, an ODA intermediate
dynein chain co-assembled with another IC [DNAI1] during the
ﬁrst steps of cytoplasmic ODA pre-assembly7,30,39. Co-expression
of GFP-tagged human PIH1D3 and Myc-tagged human DNAI2
in HEK293 cells followed by co-immunoprecipitation (IP)
showed an interaction between the two proteins (Fig. 5c),
which was also conﬁrmed with swapped tags (Fig. 5d),
supporting a role for PIH1D3 in axonemal dynein assembly.
Since modelling predicts that the Asp133Tyr missense mutation
identiﬁed in patient DCP68, which replaces a small charged
residue (Asp) with a polar aromatic residue (Tyr), is within
the CS in a high conﬁdence conserved predicted surface of
PIH1D3 that mediates protein–protein interactions (Fig. 1b;
Supplementary Fig. 4a,b), we tested whether introduction of this
missense mutation could alter the ability of PIH1D3 to interact
with DNAI2. We found that the PIH1D3–DNAI2 interaction was
destroyed by introduction of the missense mutation (Fig. 5c).
Correspondingly, p.Asp133Tyr is predicted as 1.0 ‘probably
damaging’ using Polyphen-2 (ref. 40) and 0.05 ‘deleterious’
according to SIFT41, consistent with a high level conservation in
multiple ciliate species across Asp133 (Fig. 1b; Supplementary
Fig. 4b). Similar results were obtained with three other deleterious
(nonsense, frameshift) human PIH1D3 mutations identiﬁed in
this study (Fig. 5c), indicating the functionally destructive nature
of all four DNA variants that were modelled.
Mutations in PIH1D3 can result in partial IDA assembly.
Having placed human PIH1D3 into the earliest steps of the
DNAI2-ODA cytoplasmic assembly process alongside DNAAF2,
a ﬁnding also supported by previous work in mice30, we next
sought higher resolution understanding about the dynein arm
defects in PIH1D3-mutated human cilia. We used electron
tomography averaging to create a three-dimensional map of
the axonemal 96 nm repeat containing the entire IDA, from
available tissue of PCD12 II:1 (p.Glu43*) and GVA30 II:1
(p.Ile164Leufs*11). Fig. 6a,b shows a representative image of
PCD12 II:1 (p.Glu43*), compared with a healthy control
(Supplementary Fig. 13). There were generally few IDAs
available for imaging, but we were able to detect them in some
sections. In imaging of GVA30 II:1, tomograms only captured
full absence of the whole IDA along with absent N-DRCs
(nexin–dynein regulatory complex) and ODAs (Fig. 6d).
However, imaging of PCD12 II:1 revealed three different
patterns of IDA assembly in the tomograms, with ODAs being
present in all imaging. The entire IDA plus N-DRC were either
entirely present (Fig. 6d, PCD12 #5–#7), entirely absent (Fig. 6d,
PCD12 #1 and #2) or else a partial IDA assembly was seen. Partial
IDA assembly found in 2 out of 7 tomograms (Fig. 6d, PCD12 #3
and #4) showed a consistent pattern of loss of the a and b
subunits of IDA dynein I1 (also known as f) and IDA dynein g.
Dynein d loss was undetermined, being either present or absent
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14279 ARTICLE
NATURE COMMUNICATIONS | 8:14279 | DOI: 10.1038/ncomms14279 |www.nature.com/naturecommunications 7
(Fig. 6a,d). Electron density mapping further conﬁrmed the
presence of all IDA and ODA components except I1/f a, I1/f b
and the d and g subunits in tomogram #3 (Fig. 6c). This partial
IDA assembly is consistent with Chlamydomonas data suggesting
different cytoplasmic axonemal dynein assembly factors might
speciﬁcally assembly distinct sets of IDA dynein subunits22.
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Figure 4 | Conserved function for PIH1D3 in vertebrate cilia motility and dynein arm assembly replicating the human disease. (a) Comparison of a
representative hi1392Tg control sibling (ctl sib, top), and a hi1392Tg mutant (bottom) harbouring a transgenic insertion in the pih1d3 (previously known as
twister) gene, at 48 h post fertilization (48 hpf). Mutants display an abnormally curved body axis (black arrow), pronephric cysts (white arrow), abnormal
otolith formation (black arrowhead). (b–f) Cilia defects are evident in hi1392Tg mutants at 48 hpf, with the grey bars in a highlighting areas used for
pronephric cilia imaging shown in b–f. Cilia motility defects are evident in representative kymographs recorded in hi1392Tg mutant siblings (c,d) compared
with hi1392Tg control siblings (b), created from 0.5-s, 1,000 fps videos of single pronephric cilia bundles beating in 48 hpf (representative of 16 recordings).
Mutants had mainly static cilia (c) with an occasional cilia showing retained reduced beating (d). Also see Supplementary Videos 6–9. (e,f) TEM of 48 hpf
pronephric cilia cross-sections from the same area reveal a reduction and loss of outer and IDAs (arrowheads) in hi1392Tg mutants (f) compared with
control siblings where the arms are visible (e). Scale bar, 50 nm. (g) Quantiﬁcation of common phenotypes of hi1392Tg mutant embryos (red columns)
compared with control sibling embryos (blue columns). hi1392Tg mutant embryos display 64–84% levels of abnormal (that is, absent or reverse) cardiac
looping, pronephric cysts and otolith malformations, while this was never, or rarely, seen in control siblings. Otolith malformation was recorded if there were
more or less than two observed. Columns represent data from three separate experiments assessing phenotype in 48 hpf embryos (n¼40–71 per
experiment). Error bars show standard deviation with t-test, P-value *o0.05. (h) The insertion hi1392Tg creates a null allele: RT-PCR of a pool of 15
embryos indicates a complete lack of pih1d3 transcript expression in hi1392Tg mutants compared with a pool of 15 control siblings. (i–k) Examples of
clutches of 72 hpf embryos from hi1392Tg/þ crosses injected at one-cell stage with 10 pg of human PIH1D3mRNA show a reduction in mutant phenotypes
(j) compared with non-injected hi1392Tg control siblings (i), with representative embryos with a straight, ventral curve, or mild curve phenotype shown in k,
upper panel. PCR genotyping in all three of these groups shows the lower hi1392Tg insertion allele band present, but the upper control allele band is present
only in the straight-tailed siblings (k, lower panel). M, DNA size marker; NTC, non-template control.
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Figure 5 | Golgi-localised PIH1D3 is upregulated during ciliogenesis and forms a complex with DNAI2 destroyed by disease-causing mutations. (a)
Immunoﬂuorescence confocal microscopy analysis in dissociated airway (nasal) epithelial cells from controls shows no co-localization of PIH1D3 (red) with
the cis-Golgi marker GM-130 (top panel, green). However, co-localization is seen using the trans-Golgi marker protein TGN-46 (middle panel, green),
implying PIH1D3 is present within the late rather than early/medial Golgi. The affected individual PCD12 II:1 showed no gross disruption of trans-Golgi
staining as a result of PIH1D3 mutation using co-localization studies of TGN-46 (green) and PIH1D3 (red) (bottom panel). Nuclei in blue (DAPI). DIC
shows cell outline. Scale bars, 10mm. (b) Quantitative RT-PCR analysis of PIH1D3 in normal human bronchial epithelial cells grown on an ALI to follow their
progression from nonciliated basal cells to multiciliated epithelia over 30 days (D) in culture. Day (D) 0 is the ﬁrst day the cells are exposed to the ALI, and
typically cilia ﬁrst become visible in these cultures from day 17. The qPCR analysis compared expression of PIH1D3 to the DNAH5 and DNAI2 genes,
mutations in which are known to cause PCD. A similar increase in mRNA expression of all three genes was seen over time in ALI culture, from around day
10 with a peak at day 24. Around day 19, the apparent higher increase in PIH1D3 levels was not signiﬁcant. The fold increase in each gene’s expression was
measured in triplicate, normalized at each time point to its expression at day 0. Error bars indicate s.e.m. (c) Co-IP assays were performed on human
embryonic kidney (HEK293) cells co-transfected with an expression vector encoding Myc-tagged DNAI2 and either an empty GFP vector or GFP-tagged
PIH1D3, corresponding either to normal full-length PIH1D3 protein or mutant PIH1D3 protein carrying mutations identiﬁed in affected individuals. Anti-GFP
antibody IP was performed using a standard protocol followed by western blotting using anti-Myc antibody, showing that Myc-DNAI2 co-precipitates only
with wild-type GFP-PIH1D3 and not with GFP-PIH1D3 harbouring any of the four identiﬁed disease mutations (p.Asp133Tyr/p.D133Y, p.Ile164Leufs*11/
p.I164Lfs*11, p.Trp89*/p.W89* and p.Glu43*/p.E43*). (d) A reciprocal co-transfection of Myc-tagged wild-type PIH1D3 into HEK293 cells with either
empty GFP vector or GFP-tagged DNAI2 followed by anti-GFP IP and anti-Myc western blotting conﬁrmed the co-IP between Myc-PIH1D3 and GFP-DNAI2.
MW, molecular weight marker. kDa, kilodaltons. Asterisks in c,d indicate the immunoprecipitated proteins (labelled on the right). Uncropped blots can be
found in Supplementary Fig. 14.
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Discussion
Here we report different approaches taken across three centres
to identify the cause of disease in a large cohort of PCD
patients. This identiﬁed protein-altering mutations in PIH1D3,
a previously uncharacterized X-linked gene in humans. X-linked
transmission of PCD was previously suggested42 and RPGR
mutations can cause syndromic X-linked PCD with retinitis
pigmentosa43, but PIH1D3 mutations are the ﬁrst reported
molecular cause of X-linked non-syndromic PCD. PIH1D3
mutations may be a prominent cause of X-linked PCD, since a
small targeted screen in this study for mutations in affected males
with PCD due to lack of dynein arms so far unexplained at the
molecular level detected PIH1D3 mutations in 9.5% of cases.
The affected males carrying PIH1D3 mutations
displayed deﬁcient mucociliary clearance, situs inversus and
asthenozoospermia, indicating that in humans the single X-linked
PIH1D3 participates in axonemal dynein assembly in both
the respiratory system and testis, as well as in laterality
determination. In contrast mice have two PIH1D3 homologues,
a testis-restricted mouse Chr. 1 Pih1d3 being essential for dynein
assembly in the sperm ﬂagellum, while mouse Chr. X Pih1h3b is
expressed in testis and also in ciliated tissues (lung, brain,
oviduct) but cannot compensate to rescue sperm motility. In the
Human Protein Atlas44 human PIH1D3 is expressed in ciliated
tissues, being highest in lung, fallopian tube and testis, supporting
our evidence that PIH1D3 function in humans, unlike in mice, is
not split between two isoforms.
Several other lines of evidence in this study reveal the possible
biological role for PIH1D3 in cilia and ﬂagella assembly. PIH1D3
expression is upregulated in parallel with other PCD genes during
human respiratory epithelial ciliogenesis. PIH1D3 is exclusively
cytoplasmic in multiciliated respiratory epithelial cells,
a localization disrupted in PIH1D3-mutated cilia. PIH1D3 is
highly conserved, as conﬁrmed by recapitulation of structure and
motility defects in PIH1D3-mutated human cilia and in hi1392Tg
zebraﬁsh pih1d3-null mutants, and the phenotypic rescue of
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Figure 6 | PIH1D3 mutations cause a failure of speciﬁc dynein components to assemble into the IDA. (a) Electron tomography based three-dimensional
map of the axonemal 96 nm repeat (indicated by dashed white lines) generated from an averaged tomogram (tomogram PCD12 #4 which is also shown in
d), from individual PCD12 II:1 harbouring the PIH1D3 mutation p.Glu43*. The data reconstruction displays the IDA coloured using Chimera software,
showing the absence of the a and b subunits of dynein I1 (also known as f), in addition to dynein g, as explained in b. (b) A diagram of the 96 nm repeat of
the human axoneme shown in both longitudinal (left) and transverse (right) section, based on imaging of normal tomograms (see Supplementary Fig. 13)
and current published literature. ODAs are depicted in blue, IDAs in red with the inner arm dynein components absent from individual PCD12 II:1 shown in a
lighter pink shade. The nexin link/dynein regulatory complex (N-DRC) is shown in yellow, with radial spoke (RSP) complexes 1, 2 and 3 and the anchoring
microtubule doublets in grey. (c) Electron density analysis along the 96 nm repeat (boxed), showing in longitudinal section the presence of all inner and
ODA components from PCD12 tomogram #7 and the absence of the I1/f a, I1/f b, d and g subunits (boxed) from PCD12 tomogram #3, taken from the
tomograms represented in d. Dashed line shown for orientation compared with a. (d) Representation of the presence or absence of IDA axonemal
components in different tomograms taken from patients PCD12 II:1 (tomograms #1–#7) and GVA30 II:1 (tomograms #1, #2). IDAs were not present
in the axonemes of cilia from GVA30 II:1, whilst there was more variability in PCD12 II:1 and IDA partial loss always involved non-assembly of dyneins
I1/f, I1/f and g.
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zebraﬁsh mutants by human PIH1D3. Affected boys and the
zebraﬁsh model both show that PIH1D3 mutations result in loss
of ODAs and IDAs. Ultrastructural studies detected some
variation in the degree of ODA versus IDA loss in different
patients carrying PIH1D3 mutations, which might be explained
by their different genetic backgrounds or by different severity of
speciﬁc mutations. Its cytoplasm localization and link to loss of
dynein arms indicate that PIH1D3 is part of the same pathway as
axonemal dynein assembly factors including DNAAF2–DNAAF4
that are likely co-chaperones of HSP90 (refs 25,26). Mutations in
DNAAF2 and DNAAF4 also cause PCD with joint ODA and IDA
loss. We have shown that like DNAAF2, PIH1D3 interacts
in vitro with DNAI2, an intermediate dynein representing one of
the ﬁrst components of the human ODA assembly process.
Clinical tomography imaging of the entire IDA shows both
complete or partial loss of IDA dyneins in PIH1D3-mutant cilia.
Little is known about human IDA assembly but similarly to
Chlamydomonas, the human IDA contains seven major species of
dyneins labelled a–g45,46. We ﬁnd in PIH1D3-mutant cilia where
there is a partially assembled IDA, that the IDA dynein subunits f
and g speciﬁcally fail to assemble. Selective assembly of different
IDA dynein subunits by different assembly factors was previously
hypothesized in Chlamydomonas22. Our data indicating that
speciﬁc assembly of dynein f and g (but not a or c) is under the
control of PIH1D3, possibly in a complementary manner to IDA
dynein assembly by DNAAF2, supports a differentiation in the
pathways of human axonemal dynein assembly, whereby different
assembly factors assemble different subunits and PIH1D3 works
alongside DNAAF2 to assemble complementary sets of IDA
dyneins.
Our combined structural and functional data have highlighted
a ciliary role for PIH1D3 in assembly of both the IDAs and
(HSP90)2
(HSP90)2
(HSP90)2
R2TP
Tah1/RPAP3
Pih1/PIH1D1
TPR
a
b
c
Rvb1/Rvb2
CS
TPRCS
TPRCS
CS
CS CS PIH
PIH
PIKKsTel2
DNAAF4
PIH1D3
DNAAF4
DNAAF2
ODA
IDA f, g
Axonemal
dynein
assembly
?
ODA
IDA c
Axonemal
dynein
assembly
?
?
Figure 7 | Proposed model of PIH1D3 function in HSP90-mediated axonemal dynein assembly. PIH1D3 may participate in an R2TP-like co-chaperone
complex composed of TPR (tetratricopeptide repeat), CS (CHORD-containing proteins and SGT1) and PIH1 (protein interacting with heat shock protein
90)-containing proteins to chaperone HSP90 for pre-assembly of axonemal dyneins in the cytoplasm, before their IFT-associated import into motile cilia
and ﬂagella. The proposed model compares PIH1D3 to two other cilia dysmotility-associated CS/PIH proteins mutated in PCD, DNAAF2 and DNAAF4
which are known to interact. (a) The yeast R2TP complex forms a multi-protein co-chaperone (purple box, human orthologs also shown) that recruits
HSP90 dimer for activation of phosphoinositol-kinase like kinases (PIKKs) through a novel phosphorylation motif (red spot) in Tel2 that associates with the
PIH domain of Pih1. (b) A structurally homologous co-chaperone DNAAF2/DNAAF4 module is proposed that may recruit HSP90 and HSP70 to axonemal
dynein assembly. The phospho-motif binding site is conserved in the DNAAF2 PIH domain (red spot), although the phosphorylated partner is unknown. (c)
CS domain similarity between PIH1D3 and DNAAF2 shows PIH1D3 may participate in a distinct co-chaperone module also required for axonemal dynein
assembly. PIH1D3 does not contain a PIH domain, therefore, a different motif may be used to link to other proteins within the dynein assembly pathway—
the unstructured N terminus of PIH1D3, shown as a ribbon, is predicted to become structured on binding of a protein partner. The PCD-associated mutation
p.Asp133Tyr (red star) within the CS domain disrupts interaction between PIH1D3 and DNAI2, an early component of axonemal dynein assembly. It is
plausible that like DNAAF2, PIH1D3 could serve its function by an interaction with DNAAF4 (grey box). Biochemical analysis in Chlamydomonas and
tomography data presented here suggest DNAAF2 and PIH1D3 are both involved in ODA assembly, and also in assembly of speciﬁc IDA dyneins. Boxes
with solid lines represent known complexes and boxes with dashed lines possible complexes. ODA, outer arm dyneins; IDA, inner arm dyneins.
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ODAs. Recent analysis suggesting two known assembly factors
DNAAF2 and DNAAF4 might form an R2TP-like complex for
dynein assembly26 helps further deﬁne the possible function of
PIH1D3 within this pathway (Fig. 7). First described in yeast, the
R2TP co-chaperone regulates essential HSP90-related functions
to direct the assembly of many multi-subunit complexes,
including the phosphatidylinositol-3-kinase-like kinases (PIKKs)
for signal transduction23. HSP90 is a molecular chaperone that
folds and activates several hundred client proteins involved in
many cellular processes, and its speciﬁcity of action is determined
by numerous co-chaperones that regulate its ATPase activity and
recruit the proteins it is required to fold47,48. In human R2TP,
PIH1D1 acts as an adaptor linking HSP90 and RPAP3 (Tah1 in
yeast) to RUVBL1 and RUVBL2 (yeast Rvb1/Rvb2) (Fig. 7a)23.
The PIH domain of yeast Pih1 (human PIH1D1) was recently
resolved as a phosphopeptide-binding domain that associates
with a novel phosphorylation motif (DpSDDxF) in Tel2 to
regulate PIKKs (Fig. 7a)26. Recruitment of R2TP to HSP90 is
mediated through the C terminus CS domain of Pih1/PIH1D1
by TPR protein Tah1/RPAP3 that binds a conserved motif
(MEEVD) of HSP90.
CS/TPR-containing DNAAF4 and CS/PIH-containing
DNAAF2 are similar to the TPR domain protein RPAP3 and
the CS/PIH protein PIH1D1, and evidence that the two interact
with each other and with HSP90 and HSP70 (refs 9,24) suggests
they could form an R2TP-like co-chaperone complex partici-
pating in axonemal dynein assembly25,26 (Fig. 7b). The phospho-
motif binding site identiﬁed in Pih1/PIH1D1 (ref. 26) is
conserved in the DNAAF2 PIH domain, indicating a similar
function in mediating phosphorylation-dependent protein–
protein interactions, though the phosphorylated partner is
unknown (Fig. 7b, red dot). The interaction of DNAAF2 with
DNAI2 could indicate its link into the dynein assembly pathway
(Fig. 7b). In the case of PIH1D3 (Fig. 7c), sequence and structural
homology between its CS domain and that in DNAAF2 suggests
that it could also interact with HSP90 though a TPR-containing
intermediary (possibly but not necessarily DNAAF4), thereby
acting as a co-chaperone recruiting HSP90 chaperone function
into axonemal dynein assembly. The p.Asp133Tyr missense
change that disrupts PIH1D3 interaction with DNAI2 conﬁrms
the functional importance of this residue within the PIH1D3 CS
domain that might link directly to dynein assembly or indirectly
via another assembly factor (Fig. 7c, red star).
By inference to the mouse testis-speciﬁc PIH1D3 homologue30,
it is possible that human PIH1D3 is not associated with
DNAAF1, DNAAF2 and DNAAF3, and that it functions
separately during the assembly of dynein arm complexes. We
ﬁnd PIH1D3 is essential for assembly of the ODAs, and for IDA
assembly it appears more strongly associated with assembly of
only speciﬁc IDA subunits, the IDA dyneins f and g (Fig. 7c).
Chlamydomonas biochemistry has previously suggested that
DNAAF2 speciﬁcally assembles ODAs and IDA dynein subunit
c (Fig. 7b)7. Our data appear to conﬁrm some complementarity
amongst human assembly factors as well, since isolated loss of
dynein c was never seen in the PIH1D3-mutant cilia of PCD12
II:1 (Fig. 6). The remaining human IDA dyneins could be
assembled speciﬁcally by other assembly factors and no human
ortholog has yet reliably been identiﬁed for MOT48, which
is a third PIH-domain cytoplasmic dynein assembly factor of
Chlamydomonas that appears to assemble its other IDA dyneins,
although MOT48 overlaps somewhat with DNAAF2 since it is
thought to speciﬁcally assemble IDA dyneins b, c, d and e22,30.
In conclusion, we propose that PIH1D3 is a cytoplasmic
protein involved in early axonemal dynein arm assembly as a
likely HSP90 co-chaperone participating to assemble ODAs and
certain IDA dynein subunits. PIH1D3 mutations affect its
interaction with protein partner(s) in dynein assembly and give
rise to a classic form of PCD disease with dynein arm loss.
PIH1D3, therefore, joins the family of human cytoplasmic
PIH/CS dynein assembly factors, probably acting in a complex
in a similar manner to the putative DNAAF2–DNAAF4
co-chaperone. We propose that it could be re-named DNAAF6
to prevent confusion about its structural domains. Better
understanding of dynein assembly factors and their chaperone-
mediated interactions in PCD may provide an important target
for therapy in future. Our ﬁndings of X-linked PCD have clinical
importance for improved counselling of individuals affected by
PCD and their families, in what has up until now been described
as a largely autosomal recessive condition. PIH1D3 should be
prioritized for mutational screening in PCD cases lacking dynein
arms and in cases of PCD with a suggestive X-linked inheritance
pattern.
Methods
Patients and sample collection. Individuals included in the study had a clinical
diagnosis of PCD conﬁrmed by standard clinical diagnostic criteria documenting
typical symptoms of neonatal respiratory distress and chronic respiratory disease
features including rhinosinusitis, re-occurring airway infections and productive
cough, otitis media and bronchiectasis. Clinical test results included nasal nitric
oxide measurements, medical imaging, in addition to light, electron and immu-
noﬂuorescence microscopy to detect ciliary motility and analyse ciliary structure.
For studies of affected individuals and their families, signed and informed consent
was obtained from all participants before history recording, blood drawing and
nasal biopsy, using protocols approved by the ethics review boards of the Uni-
versity Medical School in Geneva (Switzerland), the Institute of Child Health/Great
Ormond Street Hospital, London (UK) (#08/H0713/82) and the Comite´ de Pro-
tection des Personnes CPP Ile-de-France III (France) (approvals no. CPP07729 and
CPP02748).
Next-generation sequence analysis. DNA was extracted from whole blood of
affected individuals and family members by standard methods, with automated
platforms such as Qiagen Autopure LS and NucliSENS used for the Geneva cohort.
In the UK, the PCD12 sample was included in a cohort of 43 affected individuals
subject to whole-exome sequencing as part of the UK10K project49. PCD392 was
one of 48 affected individuals screened by targeted sequence capture. This used the
SureSelectXT system (Agilent) and sequence capture libraries designed using the
Agilent SureDesign wizard, to capture the full transcript of 640 target genes plus
25 basepairs (bp) at each intron–exon boundaries. A total of 25 ng of genomic
DNA was fragmented with QXT enzyme and tagged with adaptors for initial
ampliﬁcation. Libraries were captured and sequencing performed using standard
protocols for the Illumina HiSeq platform (paired ends, 2 150 bp). Barcoding
allowed multiplexing of eight cases per ﬂow cell. Sequence data was analysed using
an in-house pipeline50 with sequence reads in FASTQ format aligned to the
reference human genome (hg19) using BWA (0.6.1-r104) and default settings51.
Variant calling was performed across the entire region of interest using VarScan2
(V.2.3.7) set at minimum 30 coverage, minimum ﬁve alternate reads, minimum
phred-like base-quality of 20 (ref. 52). Variant calls in VCF format were then
annotated using Ensembl Variant Effect Predictor (V.73) and the output parsed
using an in-house script, which converts the annotated VCF ﬁle into Excel format
for subsequent variant ﬁltering and prioritization53. In Geneva, genomic DNA of
59 affected individuals (belonging to 47 families) was fragmented by sonication to
200 bp fragments then liquid phase captured against whole human exome probes
to select all coding sequences (SureselectXT Target Enrichment System Version 1.2,
Agilent). Sequencing was performed on an Illumina HiSeq 2000 instrument (paired
ends, 2 95 bp). Each exome library was indexed, separated into two equal halves
and sequenced in two different lanes, up to ﬁve half-libraries were sequenced in
each HiSeq lane. The raw results were analysed using a local bioinformatics
pipeline, which as previously described16 combines published algorithms in a
sequential manner (BWA for map reads, SAMtool for detection of variants, Pindel
for the detection of indels, ANNOVAR for annotation of sequence changes). The
entire coding sequence corresponding to RefSeq
(http://www.ncbi.nlm.nih.gov/refseq/) coding genes was used as the reference for
the calculation of coverage and reads on target.
In both centres, for subsequent ﬁltering of variants, only exonic and splicing
variants (±10 bp of the intron–exon boundary) were retained for further analysis.
These were ﬁltered to exclude synonymous variants, variants with a minimum
allele frequency Z0.01 in dbSNP version 137, 1000Genomes (http://
1000genomes.org/), local databases and variants found within segmental
duplications of the genome. Minor allele frequency was then checked on Exome
Variant Server (http://evs.gs.washington.edu/EVS/) and ExAC (http://
exac.broadinstitute.org/) databases, as well as in VariantMaster54 in Geneva, to
further ﬁlter for variants common among the affected individuals. Final ﬁltered
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variants were evaluated individually based on the predicted pathogenicity scores
provided by a number of softwares including SIFT, PolyPhen-2 and Mutation
Taster, their presence in HGMD (http://www.hgmd.cf.ac.uk/ac/index.php) and the
literature, focusing on functional data. Evolutionary conservation scores were
provided by PhyloP and GERPþ þ .
Whole-genome SNP-array analysis. Patients were genotyped for copy number
variations with the HumanOmniExpress 24 BeadChip from Illumina and the data
were analysed with the Genome Studio and CNV partition 3.1.6 softwares
(Illumina).
Sanger sequencing. Sanger sequencing of custom-designed PIH1D3 amplicons
(NM_001169154) conﬁrmed potentially disease-causing variants in probands and
allowed segregation analysis in their families. Primers were designed using Primer
3 (http://primer3.ut.ee/) and are listed in Supplementary Table 3 with PCR
conditions available on request. Sequences were analysed and compared with
controls using Sequencher software (Gene Codes Corporation, Ann Arbor, MI,
USA) in UK patients, Mutation Surveyor (SoftGenetics, LLC) and Staden (http://
staden.sourceforge.net/) in the Geneva patients and Seqscape software (Applied
Biosystems, Foster City, USA) in the French patients.
Immunoﬂuorescence analysis. All antibodies used are listed in Supplementary
Tables 4 and 5. Respiratory epithelial cells obtained by nasal brush biopsy and
suspended in cell culture media were air dried onto glass slides and stored at
 80 C until use. Immunostaining on the slides was performed as described55.
The cells were incubated with primary antibodies overnight at room temperature at
the dilutions listed in Supplementary Table 4, then with secondary antibodies
diluted at 1:1,000 dilution for an hour. Cells were ﬁnally washed ﬁve times with
PBS, mounted in ProLong Gold Antifade Mountant with DAPI (ThermoFisher
Scientiﬁc) and confocal images were taken using a Zeiss LSM 710 (Zeiss,
Cambridge, UK). Immunoﬂuoresence analysis in Supplementary Fig. 3 veriﬁed a
Sigma PIH1D3 antibody by speciﬁc detection of PIH1D3 at the expected molecular
weight.
cDNA cloning and site-directed mutagenesis. Fully sequenced human PIH1D3
(clone 5173807; Genbank NM_001169154) and DNAI2 (clone 5752153; Genbank
NM_023036) cDNA clones were purchased from Mammalian Gene Collection
(GE Healthcare) for Gateway Cloning. PCR products were ampliﬁed using PWO
high-ﬁdelity Taq Polymerse (Roche), subcloned into Gateway entry vector
(ThermoFisher) and recombined with pcDNA-DEST53 (ThermoFisher) and
pCMV-Myc (Clontech) Gateway Vector via LR Clonase II encoding GFP and Myc
N-terminal epitope tags, respectively.
Primers for mutagenesis were designed according to the QuikChange Primer
Design Tool (Agilent Technologies). Tagged plasmids were ampliﬁed using KAPA
HiFi DNA Polymerase (KAPA Biosystems) according to the manufacturer’s
directions. Ampliﬁed products were gel puriﬁed and Dpn1 digested for 2 h before
transforming into competent XL1-Blue cells (Stratagene). All cDNA and mutant
clones were veriﬁed by Sanger sequencing. cDNA cloning and site-directed
mutagenesis primers are listed in Supplementary Table 3.
Cell culture and transfection. Human embryonic kidney cells (HEK293T,
American Type Culture Collection) were grown to conﬂuence in DMEM
(Life Technologies) supplemented with 10% fetal bovine serum and 1% penicillin–
streptomycin antibiotic (Invitrogen). Cultures were plated at a density of 6 105
cells per well in a 6-well plate. Cells were transfected with plasmids encoding
GFP-tagged cDNA constructs, or both Myc- and GFP- tagged plasmids were
co-expressed for co-IP assays. DNA (2mg) was added to each well with 8 ml of
Lipofectamine 2000 reagent (Thermo Scientiﬁc) in OptiMEM-1 (Invitrogen) and
4 mg DNA (each at 2 mg) for co-expression studies. Within 48 h, cells were collected
in 1 PBS and lysed in 300 ul of 20mM Tris–Cl (pH 7.4), 50mM NaCl and 1%
NP40 supplemented with protease inhibitor cocktail (Sigma). Lysates were
centrifuged at 16,000g for 15min at 4 C, aliquoted and stored at  20 C until use.
Co-IP and immunoblotting. IP assays were performed using Dynabeads Protein G
beads (Novex). Brieﬂy, 20 ml of Dynabeads were washed three times in IP buffer
(50mM Tris 7.4, 150mM NaCl, 1mM EDTA, 0.5% sodium deoxycholate and 1%
NP40). Approximately 2mg of co-expressed lysate with protease inhibitor cocktail
(Sigma) was added to pre-washed beads to pre-clear on a rotator for 2 h at 4 C.
Subsequently, 50ml of beads were brieﬂy washed three times in IP buffer and then
incubated with 1 mg of mouse IgG anti-GFP (clones 7.1 and 13.1, Roche) antibody
at room temperature for 1.5 h. Antibody-bead complexes were gently washed three
times in IP buffer before incubating with pre-cleared lysate overnight at 4 C. Bead
complexes were gently washed ﬁve times in IP buffer and resuspended in 2
Laemmli sample buffer (BioRad), 1 ml of 2-mercaptoethanol (Sigma) and heated for
10min at 95 C to dissociate the complex from the beads. Beads were separated on
a magnet and lysates were then by electrophoresed on 10% SDS–PAGE gels,
transferred to nitrocellulose membranes and blocked in 5% skimmed milk, 3% BSA
dissolved in PBS-Tween for 2 h at room temperature before immunoblotting
overnight at 4 C with mouse anti-Myc (9E10, ThermoFisher). For
immunoblotting, 20 mg of lysate was resuspended in 2 Laemmli sample buffer
(BioRad), 1 ml of 2-mercaptoethanol (Sigma) and heated for 5min at 95 C and the
protocol continued similarly to the IP assay. Membranes were washed four times
(10min each) then incubated with anti-mouse HRP or anti-sheep HRP secondary
antibody for 45min at room temperature. Membranes were then washed ﬁve times
and developed by Pierce ECL Western Blotting Substrate (ThermoFisher Scien-
tiﬁc). Images were developed on X-ray ﬁlms (GE Healthcare).
The following antibodies were used: mouse monoclonal anti-GFP (clones 7.1
and 13.1, Roche), mouse monoclonal anti-Myc (1:1,000, clone 9E10, Merck
Millipore), rabbit polyclonal anti-PIH1D3 (1:400, HPA051099, Sigma), mouse
anti-GAPDH (1:1,500, clone 6C5, Merck Millipore), donkey anti-rabbit HRP
antibody (1:5,000, NA934, GE Healthcare) and sheep anti-mouse HRP antibody
(1:5,000, NXA931, GE Healthcare).
Air–liquid interface (ALI) cultures. Normal human bronchial epithelial (NHBE)
cells were obtained from Lonza. Cultures were transformed at passage 2 with Bmi1
and maintained on collagen-coated plates with Bronchial Epithelial Growth Media
(Lonza) for 7 days to grow to conﬂuence. Cells were seeded at a density of 5 105
onto 24-well collagen-coated transwell inserts (Costar, Corning, USA). When
conﬂuent after 48 hr cell the cultures were exposed to an air-liquid interface (ALI)
as previously described56 by removing medium from their surface (apical chamber)
and replacing the medium in the basal chamber with ALI medium (1:1 ratio of
DMEM 4.5 g l 1 D-glucose:Bronchial Epithelial Growth Media containing 100 nM
all-trans retinoic acid (Sigma-Aldrich, UK)). Cells were ALI cultured for the next
30 days.
Quantitative RT-PCR analysis. Total RNA was isolated from ALI culture pellets
using Trizol Reagent (Invitrogen) and used to produce complementary DNA with
Omniscript (Invitrogen). RT-qPCR primers were designed using Primer-BLAST
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) to ensure speciﬁcity and primer
sets were optimized across a range of cDNA concentrations by generating standard
and melt curves per gene. All real-time qPCR reactions were carried out with a
CFX96 Touch Real-Time PCR Detection instrument (Biorad) with samples set up
in triplicates in 20ml reactions containing 2 iQ SYBR Green Supermix (Biorad), 3
picomolar of 100mM primer mix (forward and reverse primers) and 500 ng of
cDNA. GAPDH was used as an endogenous control for normalization between
target gene expression levels. Data acquisition of the ﬂuorescent signal was
performed at the end of the run. Double delta CT calculations were measured as
logarithm and then converted to fold change of 100, after untreated control levels
were subtracted from target levels. Primers used in RT-qPCR experiments are listed
in Supplementary Table 3.
Zebraﬁsh analysis. All zebraﬁsh (Danio rerio) experiments were approved by
the Institutional Animal Care and Use Committee (IACUC) of Yale University.
Husbandry was carried out according to standard protocols57. A human
rescue expression vector was created by cloning human PIH1D3 (PCR primers
50-CACCAGGATCCATGGAATCTGAAAATATGGAT-30 and 50-AGGCTCGAG
TCAGAAGAAATTAGCAATATC-30) into the pCS2þ vector between BamHI
and XhoI restriction endonuclease sites. For zebraﬁsh pih1d3, total RNA was
isolated from wild-type TuAB embryos, followed by cDNA synthesis with
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). PCR
products using pih1d3-speciﬁc primers 50-(ggatcccatcgattcg)ATGGAGGGTCTCG
CGTCC-30 and 50-(actatagttctagaggc)TCAGGTCAGATTAATGCAGTCCA-30
were cloned using the Gibson assembly kit (NEB) into an EcoRI- and XhoI-
digested pCS2þ vector. Plasmids were linearized with NotI, followed by 50cap
mRNA synthesis using the SP6 mMESSAGE mMACHINE kit (Ambion). Puriﬁed
mRNA was injected at 1 nl into 1-cell stage embryos. The embryos were raised at
þ 28.5 C until analysis. For genotyping, embryos were lysed with 50mM NaOH,
and analysed by duplex PCR using primers 50-TTACTACTACAATCCG
CGTCCATG-30 , 50-CAAGGTTTGTCAGGCGATAATAGAT-30 and 50-GCTAG
CTTGCCAAACCTACAGGT-30 . For mRNA expression, mRNA was puriﬁed
using Trizol (Invitrogen), followed by cDNA synthesis using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems) and PCR with primers
against full-length pih1d3, 50-ATGGAGGGTCTCGCGTCC-30 and 50-TCAGGTC
AGATTAATGCAGTCCATTG-30. For histology, 50 hpf embryos were
anesthetized and ﬁxed with Bouin’s ﬁxative overnight at room temperature. Fixed
embryos were washed with PBT (PBS and 0.1% (v/v) Tween 20), dehydrated and
rehydrated with 100% methanol, washed with PBT and embedded in JB-4 plastic
resin (Polysciences). The moulds were cut into 4 mm slices and stained with
hematoxylin and eosin. For TEM of zebraﬁsh, embryos were anesthetized and ﬁxed
in 3% glutaraldehyde and 1.5% paraformaldehyde in a 0.1M phosphate buffer (pH
7.4) and subsequently stored in 0.1M phosphate buffer supplemented with 0.01%
sodium azide for transportation. Before TEM, embryos were washed overnight and
post-ﬁxed in 1% osmium tetroxide. After dehydration, the samples were embedded
in epoxy resin. Thin sections stained with Reynold’s lead citrate were imaged with a
Jeol 1010 electron microscope. For high-speed microscopy and analysis in
zebraﬁsh, embryos were anesthetized with 0.2mlml 1 Tricaine (Sigma-Aldrich)
and mounted on microscope slides in embryo medium. DIC images were acquired
through a  40 water immersion objective on a Zeiss Observer z1 ﬁtted with a
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14279 ARTICLE
NATURE COMMUNICATIONS | 8:14279 | DOI: 10.1038/ncomms14279 |www.nature.com/naturecommunications 13
Hamamatsu Orca Flash 4.0 V2 high-speed camera. Kymographs were created from
0.5-second 1,000 fps videos using ImageJ software.
Electron tomography. Nasal brushings were chemically ﬁxed and embedded as
previously described58. In brief; biopsies were obtained from the inferior turbinate
of the nose using a cytology brush. For electron microscopy, samples were ﬁxed in
2.5% glutaraldehyde, washed with cacodylate buffer, post-ﬁxed in osmium
tetroxide and rinsed with distilled water, with centrifuging taking place between
each step. Epithelial strips were bound with 2% agar and then dehydrated and
inﬁltrated with araldite resin and embedded in araldite. Ciliated areas were selected
in survey sections before cutting dark gold-blue ultra thin sections. Ultra thin
sections (B150 nm) were stained with methanolic uranyl acetate and lead citrate
and 10 nm gold ﬁdicuals were added to aid correlation of the captured images for
tomogram generation.
Images of cilia in longitudinal section were acquired at  20,000 magniﬁcation
using a Jeol 1400þ transmission electron microscope with a mid-mount digital
camera (AMT16X). Automated Recorder software package v2.7 (Jeol Technology
Systems) was used to acquire dual axis tilt sequences between 70 and  70 in 1
increments. Tomograms were then generated using IMOD software created by the
University of Colorado59,60. Particle Estimation for Electron Tomography (PEET)
software was used to average and align particles along manually selected
microtubules61. The outcome of the PEET process is a density map, representing
an average 96 nm repeat of the selected tubule in which regular, repeated features
are emphasized. The density maps were opened within the UCSF Chimera graphics
package62. A data threshold was set for each individual map based on achieving a
balance between structural detail and background noise. The Segger tool was used
to split the volume map into distinct segments which were then isolated and
coloured to aid visualization.
Data availability. All the relevant data are available from the authors upon
request.
References
1. Ishikawa, T. Axoneme structure from motile cilia. Cold Spring Harb Perspect
Biol. doi: 10.1101/cshperspect.a028076 (2016).
2. Lucas, J. S. et al. Diagnosis and management of primary ciliary dyskinesia.
Arch. Dis. Child. 99, 850–856 (2014).
3. Boon, M. et al. MCIDAS mutations result in a mucociliary clearance disorder
with reduced generation of multiple motile cilia. Nat. Commun. 5, 4418 (2014).
4. Shapiro, A. J. et al. Laterality defects other than situs inversus totalis in primary
ciliary dyskinesia: insights into situs ambiguus and heterotaxy. Chest 146,
1176–1186 (2014).
5. Duquesnoy, P. et al. Loss-of-function mutations in the human ortholog of
Chlamydomonas reinhardtii ODA7 disrupt dynein arm assembly and cause
primary ciliary dyskinesia. Am. J. Hum. Genet. 85, 890–896 (2009).
6. Loges, N. T. et al. Deletions and point mutations of LRRC50 cause primary
ciliary dyskinesia due to dynein arm defects. Am. J. Hum. Genet. 85, 883–889
(2009).
7. Omran, H. et al. Ktu/PF13 is required for cytoplasmic pre-assembly of
axonemal dyneins. Nature 456, 611–616 (2008).
8. Mitchison, H. M. et al. Mutations in axonemal dynein assembly factor
DNAAF3 cause primary ciliary dyskinesia. Nat. Genet. 44, 381–389 (2012).
9. Tarkar, A. et al. DYX1C1 is required for axonemal dynein assembly and ciliary
motility. Nat. Genet. 45, 995–1003 (2013).
10. Horani, A. et al. Whole-exome capture and sequencing identiﬁes HEATR2
mutation as a cause of primary ciliary dyskinesia. Am. J. Hum. Genet. 91,
685–693 (2012).
11. Diggle, C. P. et al. HEATR2 plays a conserved role in assembly of the ciliary
motile apparatus. PLoS Genet. 10, e1004577 (2014).
12. Knowles, M. R. et al. Mutations in SPAG1 cause primary ciliary dyskinesia
associated with defective outer and inner dynein arms. Am. J. Hum. Genet. 93,
711–720 (2013).
13. Austin-Tse, C. et al. Zebraﬁsh ciliopathy screen plus human mutational analysis
identiﬁes C21orf59 and CCDC65 defects as causing primary ciliary dyskinesia.
Am. J. Hum. Genet. 93, 672–686 (2013).
14. Kott, E. et al. Loss-of-function mutations in LRRC6, a gene essential for proper
axonemal assembly of inner and outer dynein arms, cause primary ciliary
dyskinesia. Am. J. Hum. Genet. 91, 958–964 (2012).
15. Horani, A. et al. LRRC6 mutation causes primary ciliary dyskinesia with dynein
arm defects. PLoS ONE 8, e59436 (2013).
16. Moore, D. J. et al. Mutations in ZMYND10, a gene essential for proper
axonemal assembly of inner and outer dynein arms in humans and ﬂies, cause
primary ciliary dyskinesia. Am. J. Hum. Genet. 93, 346–356 (2013).
17. Zariwala, M. A. et al. ZMYND10 is mutated in primary ciliary dyskinesia and
interacts with LRRC6. Am. J. Hum. Genet. 93, 336–345 (2013).
18. King, S. M. & Patel-King, R. S. The oligomeric outer dynein arm assembly
factor CCDC103 is tightly integrated within the ciliary axoneme and exhibits
periodic binding to microtubules. J. Biol. Chem. 290, 7388–7401 (2015).
19. Panizzi, J. R. et al. CCDC103 mutations cause primary ciliary dyskinesia by
disrupting assembly of ciliary dynein arms. Nat. Genet. 44, 714–719 (2012).
20. Kobayashi, D. & Takeda, H. Ciliary motility: the components and cytoplasmic
preassembly mechanisms of the axonemal dyneins. Differentiation 83, S23–S29
(2012).
21. Rosenbaum, J. L. & Witman, G. B. Intraﬂagellar transport. Nat. Rev. Mol. Cell
Biol. 3, 813–825 (2002).
22. Yamamoto, R., Hirono, M. & Kamiya, R. Discrete PIH proteins function in the
cytoplasmic preassembly of different subsets of axonemal dyneins. J. Cell Biol.
190, 65–71 (2010).
23. Kakihara, Y. & Houry, W. A. The R2TP complex: discovery and functions.
Biochim. Biophys. Acta 1823, 101–107 (2012).
24. Chen, Y. et al. A novel role for DYX1C1, a chaperone protein for both Hsp70
and Hsp90, in breast cancer. J. Cancer Res. Clin. Oncol. 135, 1265–1276 (2009).
25. Vaughan, C. K. Hsp90 picks PIKKs via R2TP and Tel2. Structure 22, 799–800
(2014).
26. Pal, M. et al. Structural basis for phosphorylation-dependent recruitment of
Tel2 to Hsp90 by Pih1. Structure 22, 805–818 (2014).
27. Jaffe, K. M. et al. c21orf59/kurly controls both cilia motility and polarization.
Cell Rep. 14, 1841–1849 (2016).
28. Wu, J., Luo, S., Jiang, H. & Li, H. Mammalian CHORD-containing protein 1 is a
novel heat shock protein 90-interacting protein. FEBS Lett. 579, 421–426 (2005).
29. Garcia-Ranea, J. A., Mirey, G., Camonis, J. & Valencia, A. p23 and
HSP20/alpha-crystallin proteins deﬁne a conserved sequence domain present in
other eukaryotic protein families. FEBS Lett. 529, 162–167 (2002).
30. Dong, F. et al. Pih1d3 is required for cytoplasmic preassembly of axonemal
dynein in mouse sperm. J. Cell Biol. 204, 203–213 (2014).
31. Yeo, G. & Burge, C. B. Maximum entropy modeling of short sequence motifs
with applications to RNA splicing signals. J. Comput. Biol. 11, 377–394 (2004).
32. Salamov, A. A., Nishikawa, T. & Swindells, M. B. Assessing protein coding region
integrity in cDNA sequencing projects. Bioinformatics 14, 384–390 (1998).
33. Kamiya, R. Functional diversity of axonemal dyneins as studied in
Chlamydomonas mutants. Int. Rev. Cytol. 219, 115–155 (2002).
34. Chilvers, M. A., Rutman, A. & O’Callaghan, C. Ciliary beat pattern is associated
with speciﬁc ultrastructural defects in primary ciliary dyskinesia. J. Allergy Clin.
Immunol. 112, 518–524 (2003).
35. Sun, Z. et al. A genetic screen in zebraﬁsh identiﬁes cilia genes as a principal
cause of cystic kidney. Development 131, 4085–4093 (2004).
36. Kramer-Zucker, A. G. et al. Cilia-driven ﬂuid ﬂow in the zebraﬁsh pronephros,
brain and Kupffer’s vesicle is required for normal organogenesis. Development
132, 1907–1921 (2005).
37. Essner, J. J., Amack, J. D., Nyholm, M. K., Harris, E. B. & Yost, H. J. Kupffer’s
vesicle is a ciliated organ of asymmetry in the zebraﬁsh embryo that initiates
left-right development of the brain, heart and gut. Development 132, 1247–1260
(2005).
38. Lundberg, Y. W., Xu, Y., Thiessen, K. D. & Kramer, K. L. Mechanisms of
otoconia and otolith development. Dev. Dyn. 244, 239–253 (2015).
39. Fowkes, M. E. & Mitchell, D. R. The role of preassembled cytoplasmic complexes
in assembly of ﬂagellar dynein subunits. Mol. Biol. Cell 9, 2337–2347 (1998).
40. Adzhubei, I. A. et al. A method and server for predicting damaging missense
mutations. Nat. Methods 7, 248–249 (2010).
41. Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nat.
Protoc. 4, 1073–1081 (2009).
42. Narayan, D. et al. Unusual inheritance of primary ciliary dyskinesia
(Kartagener’s syndrome). J. Med. Genet. 31, 493–496 (1994).
43. Moore, A. et al. RPGR is mutated in patients with a complex X linked
phenotype combining primary ciliary dyskinesia and retinitis pigmentosa.
J. Med. Genet. 43, 326–333 (2006).
44. Uhlen, M. et al. A human protein atlas for normal and cancer tissues based on
antibody proteomics. Mol. Cell Proteomics 4, 1920–1932 (2005).
45. Hom, E. F. et al. A uniﬁed taxonomy for ciliary dyneins. Cytoskeleton 68,
555–565 (2011).
46. Porter, M. E. & Sale, W. S. The 9 þ 2 axoneme anchors multiple inner arm
dyneins and a network of kinases and phosphatases that control motility. J. Cell
Biol. 151, F37–F42 (2000).
47. Li, J. & Buchner, J. Structure, function and regulation of the hsp90 machinery.
Biomed. J. 36, 106–117 (2013).
48. von Morgen, P., Horejsi, Z. & Macurek, L. Substrate recognition and function
of the R2TP complex in response to cellular stress. Front. Genet. 6, 69 (2015).
49. Onoufriadis, A. et al. Combined exome and whole-genome sequencing
identiﬁes mutations in ARMC4 as a cause of primary ciliary dyskinesia with
defects in the outer dynein arm. J. Med. Genet. 51, 61–67 (2014).
50. Trump, N. et al. Improving diagnosis and broadening the phenotypes in
early-onset seizure and severe developmental delay disorders through gene
panel analysis. J. Med. Genet. 53, 310–317 (2016).
51. Li, H. & Durbin, R. Fast and accurate short read alignment with
Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14279
14 NATURE COMMUNICATIONS | 8:14279 | DOI: 10.1038/ncomms14279 | www.nature.com/naturecommunications
52. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration
discovery in cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
53. McLaren, W. et al. Deriving the consequences of genomic variants with the
Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069–2070 (2010).
54. Santoni, F. A. et al. Simultaneous identiﬁcation and prioritization of variants in
familial, de novo, and somatic genetic disorders with VariantMaster. Genome
Res. 24, 349–355 (2014).
55. Onoufriadis, A. et al. Targeted NGS gene panel identiﬁes mutations in RSPH1
causing primary ciliary dyskinesia and a common mechanism for ciliary central
pair agenesis due to radial spoke defects. Hum. Mol. Genet. 23, 3362–3374 (2014).
56. Hirst, R. A., Rutman, A., Williams, G. & O’Callaghan, C. Ciliated air-liquid
cultures as an aid to diagnostic testing of primary ciliary dyskinesia. Chest 138,
1441–1447 (2010).
57. Westerﬁeld, M. The Zebraﬁsh Book. A Guide for the Laboratory Use of Zebraﬁsh
(Danio rerio) (Univ. of Oregon Press, 2000).
58. Shoemark, A., Dixon, M., Corrin, B. & Dewar, A. Twenty-year review of
quantitative transmission electron microscopy for the diagnosis of primary
ciliary dyskinesia. J. Clin. Pathol. 65, 267–271 (2012).
59. Kremer, J. R., Mastronarde, D. N. & McIntosh, J. R. Computer visualization of
three-dimensional image data using IMOD. J. Struct. Biol. 116, 71–76 (1996).
60. Mastronarde, D. N. Dual-axis tomography: an approach with alignment
methods that preserve resolution. J. Struct. Biol. 120, 343–352 (1997).
61. Nicastro, D. et al. The molecular architecture of axonemes revealed by
cryoelectron tomography. Science 313, 944–948 (2006).
62. Pettersen, E. F. et al. UCSF chimera—a visualization system for exploratory
research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
63. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. The
Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc.
10, 845–858 (2015).
Acknowledgements
We are very grateful to the families with PCD who have participated in this study and to
the UK PCD Family Support Group for their support. We thank Celia D. Delozier,
R. Lazor and Jane Hurst for family recruitment and their present or past involvement in
the project. We thank Andrew Rogers and Emily Frost from the Royal Brompton
Hospital and Dale Moulding (UCL-GOS-ICH Confocal Microscopy Core Facility) and
Kim Harrison-Lavoie (UCL) for experimental assistance. We thank Federico A. Santoni
(University of Geneva School of Medicine and University Hospitals of Geneva) for
bioinformatics expertise. We thank Shiaulou Yuan (Department of Pediatrics, YSM) for
assistance with high-speed microscopy and SueAnn Mentone (Department of Cellular
and Molecular Physiology, YSM) for advice regarding TEM. A.B. is an NIHR Senior
Investigator and additionally was supported by the NIHR Respiratory Disease Biome-
dical Research Unit at the Royal Brompton and Hareﬁeld NHS Foundation Trust and
Imperial College London. Work by A.S. is independent research funded by a post-
doctoral research fellowship from the National Institute of Health Research and Health
Education England, and the views expressed in this publication are those of the authors
and not necessarily those of the NHS, the National Institute of Health Research or the
Department of Health. Z.S. and S.K. are supported by NIH Grants R01HL125885-01A1
and R01 DK092808-01A1. J.-L.B.is supported by a grant from the Swiss National Science
Foundation (#32003B_135709). J.-L.B., L.B., C.O. and S.A. are supported by grants from
the Milena Carvajal Pro-Kartagener Foundation of Geneva; J.-L.B. and C.O. were
supported by a grant from the Ernst et Lucie Schmidheiny foundation of Geneva. S.E.A.
and J.-L.B are supported by funds from the University Hospitals of Geneva. A.O. is
supported by the National Institute for Health Research (NIHR) Biomedical Research
Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. S.A.
is supported by grants from the Fondation pour la Recherche Me´dicale
(DEQ20120323689) and the Legs Poix from the Chancellerie des Universite´s. This
research was supported by the National Institute for Health Research Biomedical
Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust
and University College London. We acknowledge Wellcome Trust award WT091310 to
UK10K and are grateful to the UK10K consortium (investigators listed at http://
www.uk10k.org/), in particular the Rare Diseases Group, for whole-exome sequencing of
PCD patients. Please note that A.O. and H.M.M. are UK10K Rare members, but listed in
the main author group. H.M.M. was supported by grants from Action Medical Research
(GN2101), Newlife Foundation (10-11/15) and the Great Ormond Street Hospital
Children’s Charity.
Author contributions
Study concept and design was by: A.S., M.L., E.E., C.H., S.A., Z.S., L.B., J.-L.B and
H.M.M. Genetic methods performed by C.O., M.P.P., M.L., H.J.W., J.H., A.Go., L.D., J.B.,
C.G., M.G., S.C., P.D., L.T., L.Jea., B.C., M.R.F., L.Jen., C.B., T.Cu., A.O., UK10K, S.E.A.,
L.B. and H.M.M. Molecular cell biology performed by M.P.P, C.O. and M.M.M. Protein
modelling by R.D.E and C.K.V, and development of HSP90 interaction model C.K.V. and
H.M.M. Zebraﬁsh studies by S.K. and Z.S. Clinical ultrastructural studies by A.S., M.D.
and E.E.; and T.Ca. and A.S. performed all the electron tomography. A.Go., A.T., C.T.-R.,
J.-F.P., A.Ga., I.P., G.V., P.A., A.B., E.M.K.C., M.R.L., R.W., M.A., E.E., C.H. and L.B.
provided clinical data. A.S., C.K.V., S.K., Z.S., C.O., L.B., J.-L.B., S.A. and H.M.M. wrote
the manuscript. All authors approved the ﬁnal version submitted for publication.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Olcese, C. et al. X-linked primary ciliary dyskinesia due to
mutations in the cytoplasmic axonemal dynein assembly factor PIH1D3. Nat. Commun.
8, 14279 doi: 10.1038/ncomms14279 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
UK10K Rare Group
Saeed Al-Turki28, 29, Carl Anderson28, Dinu Antony3, Ineˆs Barroso28, Philip L. Beales3, Jamie Bentham30,
Shoumo Bhattacharya30, Keren Carss28, Krishna Chatterjee31, Sebahattin Cirak32, Catherine Cosgrove30,
Daly Allan28, Richard Durbin28, David Fitzpatrick33, Jamie Floyd28, A. Reghan Foley32, Chris Franklin28,
Marta Futema34, Steve E. Humphries34, Matt Hurles28, Shane McCarthy28, Dawn Muddyman28,
Francesco Muntoni32, Victoria Parker31, Felicity Payne28, Vincent Plagnol35, Lucy Raymond36, David B. Savage31,
Peter J. Scambler3, Miriam Schmidts3, Robert Semple31, Eva Serra28, Jim Stalker28, Margriet van Kogelenberg28,
Parthiban Vijayarangakannan28 & Klaudia Walter28
28The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1HH, Cambridge, UK. 29Department of Pathology, King Abdulaziz
Medical City, Riyadh, 14611 Saudi Arabia. 30Department of Cardiovascular Medicine and Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford
OX3 7BN, UK. 31University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science,
Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK. 32Dubowitz Neuromuscular Centre, UCL Institute of Child Health and Great Ormond Street Hospital,
London WC1N 3JH, UK. 33MRC Human Genetics Unit, MRC Institute of Genetic and Molecular Medicine, Western General Hospital, University of Edinburgh,
Edinburgh EH4 2XU, UK. 34Cardiovascular Genetics, BHF Laboratories, Rayne Building, Institute Cardiovascular Sciences, University College London, London
WC1E 6JJ, UK. 35University College London (UCL) Genetics Institute (UGI) Gower Street, London WC1E 6BT, UK. 36Department of Medical Genetics,
Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 2XY, UK.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14279 ARTICLE
NATURE COMMUNICATIONS | 8:14279 | DOI: 10.1038/ncomms14279 |www.nature.com/naturecommunications 15
